Hemophilia B With Inhibitor
Rare Disease·MeSH: Hemophilia B
Prevalence
3.0 / 100K
Incidence
4.0 / 100K/yr
1 drug in development·1 company·0 clinical trials
Drug Pipeline by Phase
Phase 2(1)
| Drug | Company |
|---|---|
| SerpinPC | Centessa Pharmaceuticals plc (CNTA) |
Frequently asked questions
How many drugs are in development for Hemophilia B With Inhibitor?
BioSniper tracks 1 drug in development for Hemophilia B With Inhibitor across 1 company.
What is the prevalence of Hemophilia B With Inhibitor?
The estimated prevalence of Hemophilia B With Inhibitor is approximately 3.0 per 100,000 population.
Deep-dive into Hemophilia B With Inhibitor
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis